Brought to you by 
CSL raises $A1.7bn for purchase of Talecris
27 Aug 2008
Executive Summary
Australia's CSL (vaccines) completed an $A1.7bn ($1.5bn) private equity sale to institutional investors. The company issued 47.5mm ordinary shares at $A36.75 each (a slight premium) to finance its recently announced $3.1bn purchase of Talecris (hemostasis, pulmonology, and immune disorder therapeutics).
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Vaccines
Deal Status
- Final
Deal Type
-
Financing
- Private Placement
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
CSL raises $A1.7bn for purchase of Talecris
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice